Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer
Immunology · 2024
DOI: 10.1111/imm.13832 ↗At a glance
Journal article in Immunology, 2024. Written by Stéphanie Bessoles and 5 co-authors. Institution: Université Paris Cité, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, Paris, France. Major MEDLINE topics: Antigens, CD, Apyrase, Erythropoietin, Triple Negative Breast Neoplasms. Cited 14 times so far (Crossref); 88 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Groupement des Entreprises Françaises dans la lutte contre le Cancer, Ligue Contre le Cancer.
Abstract (original language)
The adverse effects observed in some cancer patients treated with erythropoiesis‐stimulating agents such as erythropoietin (EPO) might be due to the latter's well‐known immunosuppressive functions. Here, we used a mouse model of syngeneic triple‐negative breast cancer to explore EPO's immunomodulatory role in a tumour setting. Our results showed that EPO treatment promotes tumour growth, exacerbates the ‘immune desert’, and results in a ‘cold tumour’. EPO treatment changed the immune cell distribution in peripheral blood, secondary lymphoid organs, and the tumour microenvironment (TME). Our in‐depth analysis showed that EPO mainly impacts CD4 T cells by accelerating their activation in the spleen and thus their subsequent exhaustion in the TME. This process is accompanied by a general elevation of CD39 expression by several immune cells (notably CD4 T cells in the tumour and spleen), which promotes an immunosuppressive TME. Lastly, we identified a highly immunosuppressive CD39 + regulatory T cell population (ICOS + , CTLA4 + , Ki67 + ) as a potential biomarker of the risk of EPO‐induced tumour progression. EPO displays pleiotropic immunosuppressive functions and enhances mammary tumour progression in mice.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Université Paris Cité, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, Paris, France.
- Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Hôpital Kremlin-Bicêtre, Assistance Publique-Hôpitaux de Paris, Le-Kremlin-Bicêtre, France.
- GenoSplice Technology, Paris, France.
ORCID profiles: Stéphanie Bessoles
Funding
- Groupement des Entreprises Françaises dans la lutte contre le Cancer
- Ligue Contre le Cancer
Cite
APA
Bessoles, S., Chiron, A., Sarrabayrouse, G., De La Grange, P., Abina, A. M., & Hacein-Bey-Abina, S. (2024). Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer. Immunology. https://doi.org/10.1111/imm.13832
Vancouver
Bessoles S, Chiron A, Sarrabayrouse G, De La Grange P, Abina AM, Hacein-Bey-Abina S. Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer. Immunology. 2024. doi:10.1111/imm.13832
BibTeX
@article{Bessoles2024,
author = {Bessoles, Stéphanie and Chiron, Andrada and Sarrabayrouse, Guillaume and De La Grange, Pierre and Abina, Amine M and Hacein-Bey-Abina, Salima},
title = {Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer},
journal = {Immunology},
year = {2024},
doi = {10.1111/imm.13832}
}
EUVIMED